STOCKHOLM. Umecrine Cognition AB today announces that the European Patent Office (EPO) has granted a patent covering its lead candidate drug GR3027 for the medical use in hepatic encephalopathy (HE). The granted patent will expire in 2035.
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of CNS-related disorders, today announces that Dr. Eva Arlander has been appointed as Chief Development Officer.
Umecrine Cognition announces on-line publication of Clinical trial results perteining to GR3027 safety, pharmacokinetics and CNS target engagement
STOCKHOLM. Umecrine Cognition AB is pleased to announce the publication in Psychopharmacology of clinical trial results which demonstrate that the company’s candidate drug, GR3027, reverses the brain-inhibitory effects of allopregnanolone at doses which are well tolerated and exhibit excellent pharmacokinetics.